Mounjaro's UK Release Date and the Road to Approval

Step 1: the MHRA grants the UK licence (November 2023)

Before any medicine reaches UK patients, the Medicines and Healthcare products Regulatory Agency must be satisfied it is safe, effective and manufactured to the required standard. For tirzepatide, that decision came on 19 November 2023. The licence covers weight management in adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present, think high blood pressure, type 2 diabetes, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

One misconception worth clearing up gently: some people assume Mounjaro was already widely available in the UK before this date because they'd seen it mentioned online. What they were seeing was the earlier diabetes licence, approved separately, or US coverage of tirzepatide under the brand Zepbound, a product that does not exist in the UK. If you want a clear account of when Mounjaro was released and how those earlier sightings fit into the timeline, that page walks through each milestone. You can read more about tirzepatide's mechanism and licensed uses on our tirzepatide overview page.

Following authorisation, Eli Lilly began supplying Mounjaro through the licensed UK supply chain, and private clinics and pharmacies could start prescribing. The MHRA assigned a Black Triangle (▼) to signal that, as a newly authorised medicine, it carries enhanced post-market surveillance. That designation is standard for new products and does not indicate unusual risk; it does mean any suspected side effect should be reported promptly via the MHRA Yellow Card scheme.

Step 2: NICE recommends tirzepatide, and sets the NHS eligibility criteria (December 2024)

A licence lets a medicine be prescribed; a NICE recommendation shapes whether the NHS will fund it. On 23 December 2024, NICE published Technology Appraisal 1026, recommending tirzepatide for adults in England with a BMI of 35 or above and at least one weight-related comorbidity, with thresholds set 2.5 kg/m² lower for people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds. The appraisal was updated in September 2025 to reflect the NHS commissioning timetable.

The clinical evidence behind that decision drew substantially on the SURMOUNT trial programme. In SURMOUNT-1, published in the New England Journal of Medicine, participants using the 15mg dose achieved average body-weight reductions of around 20–21% over 72 weeks, figures that moved NICE's cost-effectiveness modelling in tirzepatide's favour. Our Mounjaro treatment page sets out the full evidence picture.

Separate from the NICE criteria, private licences continue to follow the SmPC thresholds: BMI 30 or above, or 27 with a qualifying condition. A prescriber still assesses the whole clinical picture, BMI alone does not determine suitability. The NICE TA1026 guidance is publicly available if you want to read the recommendation in full.

Step 3: NHS rollout begins, and what private access looks like now

NICE approval does not mean immediate availability across all GP surgeries. England is releasing NHS access in cohorts, with the first group becoming eligible from June 2025: adults with a BMI of 40 or above and four or more of five specified conditions (high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes). A second cohort, covering BMI 35–39.9 with four or more of those conditions, opened in June 2026. Further cohorts are expected around March 2027. NHS access also requires participation in wraparound diet and activity support, and availability varies by GP practice. Scotland, Wales and Northern Ireland set their own thresholds.

For people who do not meet the current NHS cohort criteria, or who prefer not to wait, private prescriptions through a regulated pharmacy remain the main route. If you are curious about what private treatment involves, our guide to obtaining Mounjaro privately explains the consultation and dispensing process. And if you have questions about pen dates and storage once treatment starts, the detail on Mounjaro use-by dates is worth a read before your first delivery arrives.

Pricing through private providers has changed since the licence launched. Eli Lilly raised Mounjaro's UK list price from September 2025, with the highest dose's list price rising from around £122 to around £330 per four-week pen; typical private prices since then have ranged roughly £149–£375 per month depending on dose and provider, as widely reported. For context on what those figures do and don't include, there is a full breakdown on our treatment page.

Key dates at a glance

For anyone researching the tirzepatide release date specifically: the regulatory and access milestones land in a fairly short window. UK marketing authorisation: November 2023. NICE recommendation published: December 2024, updated September 2025. NHS prescribing via GP contract (QOF 2026/27): from April 2026, with uptake varying by practice. First NHS patient cohort eligible: June 2025. Second cohort: June 2026. The full historical record of these dates, including pen format and storage information relevant to patients already on treatment, is covered across our Mounjaro dates resource.

If you are considering whether treatment might be right for you now, our prescribers review consultations the same day, a real clinician reads your answers, not an automated system. Check your eligibility with a free consultation through nume.